{"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"61"},{"groupId":"BG004","value":"129"}],"units":"Participants"}],"groups":[{"description":"First-line patients were enrolled after Amendment 1 with a starting oral dose of Afatinib 40 mg daily after Amendment 2. Dose reduction scheme was defined for patients unable to tolerate this dose.","id":"BG000","title":"First-line Afatinib 40 mg"},{"description":"First-line patients were enrolled after Amendment 1 with a starting oral dose of Afatinib 50 mg daily. Dose reduction scheme was defined for patients unable to tolerate this dose.","id":"BG001","title":"First-line Afatinib 50 mg"},{"description":"Second-line patients received a starting oral dose of Afatinib 40 mg daily only after Amendment 2. Dose reduction scheme was defined for patients unable to tolerate this dose.","id":"BG002","title":"Second-line Afatinib 40 mg"},{"description":"Second-line patients received a starting oral dose of Afatinib 50 mg daily. Dose reduction scheme was defined for patients unable to tolerate this dose.","id":"BG003","title":"Second-line Afatinib 50 mg"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.0","value":"64"},{"groupId":"BG001","spread":"9.6","value":"62"},{"groupId":"BG002","spread":"14.5","value":"57"},{"groupId":"BG003","spread":"11.5","value":"61"},{"groupId":"BG004","spread":"11.1","value":"62"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"32"},{"groupId":"BG004","value":"75"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"29"},{"groupId":"BG004","value":"54"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Treated set: The patients who had taken at least one dose of afatinib were included in the treated set."}